| Name | Title | Contact Details |
|---|
Keas is the leading Health Management platform for employers. We offer Wellbeing programs, coaching, benefits integration, and wellness incentives. Keas is dedicated to helping employers reduce health costs by reducing population health risks and encouraging smarter buying choices in healthcare. With over 70% of preventable healthcare spend wasted today, Keas leverages cutting-edge technologies in data science and behavioral economics to change behavior and slash waste, once and for all.
Physician Health Partners is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.
Regency Hospital Company, LLC is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Regency Hospital Company, LLC is based in Alpharetta, GA. You can find more information on Regency Hospital Company, LLC at www.regencyhospital.com
Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency due to cystic fibrosis, lupus, lupus with glomerulonephritis, and IgA nephropathy.